Product classification

59-92-7

Product Name：Levodopa
Molecular Formula：C₉H₁₁NO₄
Purity：99%
Molecular Weight：

Inquiry

Product Details;

CasNo： 59-92-7

Molecular Formula： C₉H₁₁NO₄

Appearance： colorless crystalline powder

2-amino-3-(3,4-dihydroxyphenyl)propanoicacid 59-92-7 Powder In Medicine

Molecular Formula:C9H11NO4
Molecular Weight:197.191
Appearance/Colour:colorless crystalline powder
Vapor Pressure:7.97E-09mmHg at 25°C
Melting Point:276-278 °C(lit.)
Refractive Index:-12 ° (C=5, 1mol/L HCl)
Boiling Point:448.4 °C at 760 mmHg
PKA:2.32(at 25℃)
Flash Point:225 °C
PSA：103.78000
Density:1.468 g/cm³
LogP:0.75250

59-92-7 Usage

The chemical formula of Levodopa is C9H11NO4 which containing 9 Carbon atoms,11 Hydrogen atoms,1 Nitrogen atoms and 4 Oxygen atoms,and the molecular weight of Levodopa is 197.191. Levodopa is the standard medication clinically prescribed to patients afflicted with Parkinson’s disease. In particular, the monitoring and optimization of levodopa dosage are critical to mitigate the onset of undesired fluctuations in the patients’ physical and emotional conditions such as speech function, motor behavior, and mood stability. It derived from vanillin is widely used for treatment of Parkinson’s disease, most often in combination with peripheral decarboxylase inhibitors such as benserazide and carbidopa. The use of either levodopa or apomorphine has their own advantages and disadvantages but their effects are similar with regard to predicting chronic levodopa response.

InChI:InChI=1/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1

59-92-7 Relevant articles

Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson's disease

Abhishek Lenka,Gianluca Di Maria,Guillaume Lamotte,Laxman Bahroo &Joseph Jankovic

Expert Review of Neurotherapeutics Volume 22, 2022 - Issue 6

As levodopa is the most effective medication for treating PD, prescribers should be familiar with the tips and tricks to improve its efficacy and tolerability.

Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease

Valentina Leta, Lisa Klingelhoefer, Katherine Longardner, Marta Campagnolo, Hafize Çotur Levent, Federico Aureli, Vinod Metta, Roongroj Bhidayasiri, Guy Chung-Faye, Cristian Falup-Pecurariu, Fabrizio Stocchi, Peter Jenner, Tobias Warnecke, K. Ray Chaudhuri,

European Journal of Neurology, Volume30, Issue5 May 2023 Pages 1465-1480

Levodopa, the precursor of the neurotransmitter dopamine, is a large neutral amino acid (LNAA) that can bypass the blood–brain barrier and is converted into dopamine in the central nervous system (CNS).

59-92-7 Process route

: 63-84-3,90638-38-3
dopa

: 59-92-7,90638-38-3
levodopa

: 5796-17-8,90638-38-3
D-Dopa

Conditions

Conditions	Yield

With teicoplanin; In methanol; water; Further Variations:; Reagents; pH-values; Solvents; Product distribution;
With chiral stationary phase including isopropyl-functionalized CF₆; In methanol; acetic acid; triethylamine; acetonitrile; at 0 ℃; Purification / work up;
With Merck RP-18 WF₂₅₄S plates coated with N^τ-n-decyl-L-spinacine and Cu acetate; In methanol; water; Resolution of racemate;
With (S)-2-hydroxy-2'-(3-(N-phenylcarbamoylamino)benzyl)-1,1'-binaphthyl-3-carboxaldehyde; In dimethyl sulfoxide; stereoselective reaction; Resolution of racemate;	89.2 % ee
With (R)-2-hydroxy-2'-(3-phenylurylbenzyl)-1,1'-binaphthyl-3-carboxaldehyde; In dimethyl sulfoxide; stereoselective reaction; Resolution of racemate;	89 % ee
With ammonium formate; In methanol; at 20 ℃; pH=3.6; Reagent/catalyst; Resolution of racemate;
With perchloric acid; at 25 ℃; pH=1; Resolution of racemate;